About us
Annual Meeting Abstracts
Annual Meeting
Annual Meeting

Annual Meeting Abstracts

23rd Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology
jointly with 43rd Annual Meeting of Japanese Society of Newropsychopharmacology

October 24-26, 2013

Last Name First Name No. Title
Berk Michael SL-1 Oxidative and immune biomarkers as targets for novel therapies
Phillips Anthony G. SL-2 Stress and cognition: A critical role for the prefrontal cortex
Zohar Joseph N-SL DSM 5 and RDOC conceptual consideration and implication on diagnosis and treatment of Anxiety Disorders
Yatham Lakshmi N. CL-1 Promises of DSM.5 and the Current Realities: Implications for Bipolar Disorder Diagnosis and Treatment
REIJI YOSHIMURA C-S3-2 Predictions for responses to antidepressants: view from catecholamines, cytokines, and brain-derived neurotrophic factor
HIDENORI YAMASUE C/N-S5-2 Development of therapeutics for core symptoms of autism spectrum disorders: Clinical trials of intranasal oxytocin
TERUO HAYASHI N-S2-1 Molecular function of the endoplasmic reticular chaperone sigma-1 receptor
SHIZUKA SHIMABUKURO N-S4-4 ADHD: Where basic science meets clinical practice
TOMOYUKI FURUYASHIKI N-S8-4 Repeated stress-induced changes in dopaminergic functions in the medial prefrontal cortex in mice
SHIN ONO EN-2 The prevalence of glucose intolerance in Japanese schizophrenic patients with a normal fasting glucose level
YUTARO SUZUKI EN-3 Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics
MASAYA YANAGI AB-2 A potassium channel, Kv3.1, is reduced in schizophrenia and normalized with antipsychotic drugs; a possible new drug target for schizophrenia
Berk Michael LS2-D Preventing depressive episodes in bipolar disorder: Maintenance therapy
Yatham Lakshmi N. LS2-E Recent Advances in Diagnosis and Treatment of Bipolar Disorder
Zohar Joseph LS3-B Science and nomenclature - Could infusion of neuroscience change an outdated psychotropic classification? An update
Phillips Anthony G. ES2-B Prospects for more effective treatment of schizophrenia through innovations in neuropsychopharmacology
TAKASHI WATANABE O1-C5 5-HTTLPR genotype is the determinant of the therapeutic response and discontinuation of paroxetine initial treatment in panic disorder, not in major depressive disorder
KOICHI NISHIJIMA O1-D2 Temporal changes in serum creakine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome
KAZUNARI YOSHIDA O1-D3 Abnormal involuntary movement and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data
YUYA MIZUNO O1-D5 Polypharmacy to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Metaanalysis
TSUYOSHI MIYAOKA O3-C2 Efficacy and Safety of Yokukansan (TJ-54) in Treatment-Resistant Schizophrenia: A PANSS five-factor analysis
MUHAMMAD RASHEDUL ISLAM O3-D1 Rivastigmine improves the hippocampal neurogenesis and anti-depressivelike behaviors in olfactory bulbectomized mice
KENJI HASHIMOTO O3-D3 Role of BDNF-TrkB signaling in the inflammation-induced depression
SHIHO KITAOKA O3-D4 A role for neuron-microglia interaction through the innate immune signaling in emotional changes caused by repeated social defeat stress in mice
SHIGEKI MORIGUCHI O3-E5 Sigma-1 receptor stimulation improves depressive-like behaviors in CaMKIV null mice
MANABU FUCHIKAMI O3-E6 Pharmacological and optogenetic characterization of the critical PFC subregions underlying the rapid antidepressant actions of ketamine
KATSUTOSHI YOKOYAMA O3-C7 Milnacipran influences the indexes of I-metaiodobenzylguanidine (MIBG) scintigraphy in elderly depressed patients
YUKIE KAWAHARA O3-D12 Food reward-sensitive interaction of ghrelin and opioid receptor pathways in mesolimbic dopamine system
JUNZO WATANABE CNP1-10 The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents
TARO KISHI CNP1-22 Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
TARO KISHI CNP1-23 Augmentation of Antipsychotic Drug Action by Azapirone Serotonin1A Receptor Partial Agonists: A Meta-analysis
Yuki Matsuda CNP1-24 Updated Meta-analysis of NMDA Receptor Antagonists Interventions in Schizophrenia
TAKASHI TSUBOI CNP1-26 Predicting plasma concentration of olanzapine associated with dosage change: a population pharmacokinetic study
MASAKI KATO CNP1-34 Effect of brain volume-related SNPs of GSK3B gene on SSRI/SNRI treatment response in major depressive disorder
SHIGERU MORINOBU CNP1-35 Searching for epigenetic biomarkers in major depression: focusing on the serotonin signal transduction
WAKAKO NAKANO CNP1-61 Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: a case report
MIZUKI ASANO CNP1-68 Effects of Ramelteon on Refractory Behavioral and Psychological Symptoms of Dementia in Alzheimer Disease
YUMIKO AKAMINE CNP1-77 Different effects of two transporting inhibitors, itraconazole and cimetidine on paliperidone enantiomers pharmacokinetics
RYOICHI SADAHIRO CNP1-78 Relationship between the C3435T MDR1 polymorphism and endogenous steroid hormones in healthy subjects
YUTARO SUZUKI CNP2-3 Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia
EIJI HARADA CNP2-34 Duloxetine: Effects of Dosing and Titration on Treatment Discontinuation in Patients with Major Depression
NORIAKI SAGATA NP2-43 A single-shot minocycline inhibits methamphetamine-induced behavioral sensitization in mice
EIICHI TAIRA NP2-51 Induction of endoplasmic reticulum stress related gene CHOP/Gadd153/ ddit3 in dopaminergic cells by methamphetamine
KAZUTAKA OHI NP2-61 Impacts of the genome-wide association mega-analysis supported variants on brain morphology in schizophrenia; a comprehensive VBM analysis
HIDENAGA YAMAMORI NP2-62 Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine
MICHIKO FUJIMOTO NP2-66 Eye movement abnormalities in patients with schizophrenia
TATSUO SHIBA NP2-74 Involvement of autophagy signaling in Li2CO3-induced enhancement of the proliferation of neural stem/progenitor cells derived from the subventricular zone of adult mice
KOJI OHIRA NP2-82 Chronic fluoxetine treatment decreases parvalbumin and perineuronal nets in interneurons of frontal cortex and hippocampus of adult mice
AKIRA NAKAJIMA NP2-111 Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces oxidative stress and tau hyperphosphorylation in SAMP8 mice
YUKI KISHIKAWA NP2-113 Effects of low-dose methylphenidate on attention-deficit hyperactivity disorder (ADHD)-like behaviors in the spontaneously hypertensive rat, an animal model of ADHD
RYOTA SHINOHARA NP2-116 A role for dopamine D1 receptor in the medial prefrontal cortex in regulating stress susceptibility in mice
SATOKO HATTORI NP2-117 In vivo evaluation of CNS in alpha-CaMKII heterozygous knockout mice using manganese-enhanced magnetic resonance imaging
SATOSHI KUCHIIWA NP2-121 A novel semi-automated method for measurement and quantitative analysis of aggressive biting behavior in male and female mice
TETSUYA HASHIMOTO NP2-141 Increased hippocampal quinone reductase 2 in Alzheimer's disease
RIE ISHIKAWA NP2-144 Erasure of hippocampus-dependent fear memory by NMDA-glutamate receptor antagonist memantine
RYO FUKUMORI NP2-146 The role of uncoupling protein-2 in glutamate neurotoxicity with ischemia
YASUNORI MATSUDA NP2-155 Association of the clinical subtype and etiology for delirium with the outcome after risperidone monotherapy in patients having cancer

Jscnp Japanese